Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

There's not inherently a problem with AI being used to create calendars or even draft letters but it's important to note that ...

The Windsor Public Schools athletic director announced a new initiative, “EKGs for Elijah,” that offered free heart ...

The American Heart Association and the Arizona Cardinals gathered representatives from 12 local schools for cardiopulmonary ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

Trump Defies the #MeToo Movement With Cabinet Picks Facing Accusations Donald Trump, who was found liable for sexual abuse last year, appears determined to force a fight over the role of such ...